Unicycive Therapeutics Inc (UNCY) - Net Assets
Based on the latest financial reports, Unicycive Therapeutics Inc (UNCY) has net assets worth $37.48 Million USD as of September 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($50.61 Million) and total liabilities ($13.13 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Read UNCY total liabilities for a breakdown of total debt and financial obligations.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $37.48 Million |
| % of Total Assets | 74.06% |
| Annual Growth Rate | N/A |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | N/A |
Unicycive Therapeutics Inc - Net Assets Trend (2018–2024)
This chart illustrates how Unicycive Therapeutics Inc's net assets have evolved over time, based on quarterly financial data. Also explore UNCY asset base for the complete picture of this company's asset base.
Annual Net Assets for Unicycive Therapeutics Inc (2018–2024)
The table below shows the annual net assets of Unicycive Therapeutics Inc from 2018 to 2024. For live valuation and market cap data, see Unicycive Therapeutics Inc market cap and net worth.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | $7.43 Million | +295.09% |
| 2023-12-31 | $-3.81 Million | -717.38% |
| 2022-12-31 | $-466.00K | -102.83% |
| 2021-12-31 | $16.48 Million | +717.15% |
| 2020-12-31 | $-2.67 Million | -202.15% |
| 2019-12-31 | $-884.00K | +26.70% |
| 2018-12-31 | $-1.21 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Unicycive Therapeutics Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 9977700000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $114.00K | 1.53% |
| Other Components | $108.59 Million | 1461.27% |
| Total Equity | $7.43 Million | 100.00% |
Unicycive Therapeutics Inc Competitors by Market Cap
The table below lists competitors of Unicycive Therapeutics Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
MKH Bhd
KLSE:6114
|
$133.25 Million |
|
De Licacy Industrial Co Ltd
TW:1464
|
$133.28 Million |
|
Imperial Petroleum Inc
NASDAQ:IMPP
|
$133.31 Million |
|
VenueG Co. Ltd
KQ:019010
|
$133.35 Million |
|
Lithium Ionic Corp
V:LTH
|
$133.23 Million |
|
NOVONIX LTD SP.ADS/4
F:GC30
|
$133.20 Million |
|
MOLECULAR PARTNERS ADS/1
F:6ML0
|
$133.19 Million |
|
Endomines Finland Oyj
HE:PAMPALO
|
$133.18 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Unicycive Therapeutics Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from -3,809,000 to 7,431,000, a change of 11,240,000.
- Net loss of 36,729,000 reduced equity.
- Dividend payments of 1,095,000 reduced retained earnings.
- New share issuances of 50,683,000 increased equity.
- Other factors decreased equity by 1,619,000.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-36.73 Million | -494.27% |
| Dividends Paid | $1.09 Million | -14.74% |
| Share Issuances | $50.68 Million | +682.05% |
| Other Changes | $-1.62 Million | -21.79% |
| Total Change | $- | % |
Book Value vs Market Value Analysis
This analysis compares Unicycive Therapeutics Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 6.91x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2018-12-31 | $-1.52 | $7.67 | x |
| 2019-12-31 | $-1.04 | $7.67 | x |
| 2020-12-31 | $-1.75 | $7.67 | x |
| 2021-12-31 | $14.12 | $7.67 | x |
| 2022-12-31 | $-0.31 | $7.67 | x |
| 2023-12-31 | $-1.55 | $7.67 | x |
| 2024-12-31 | $1.11 | $7.67 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Unicycive Therapeutics Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -494.27%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 0.00%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 4.26x
- Recent ROE (-494.27%) is below the historical average (-79.82%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2018 | 0.00% | 0.00% | 0.00x | 0.00x | $-999.40K |
| 2019 | 0.00% | 0.00% | 0.00x | 0.00x | $-2.22 Million |
| 2020 | 0.00% | 0.00% | 0.00x | 0.00x | $-2.24 Million |
| 2021 | -64.50% | 0.00% | 0.00x | 1.14x | $-12.28 Million |
| 2022 | 0.00% | -1899.47% | 0.34x | 0.00x | $-18.02 Million |
| 2023 | 0.00% | -4525.04% | 0.05x | 0.00x | $-30.16 Million |
| 2024 | -494.27% | 0.00% | 0.00x | 4.26x | $-37.47 Million |
Industry Comparison
This section compares Unicycive Therapeutics Inc's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $44,828,400
- Average return on equity (ROE) among peers: -124.18%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Unicycive Therapeutics Inc (UNCY) | $37.48 Million | 0.00% | 0.35x | $133.25 Million |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-54.64 Million | 0.00% | 0.00x | $118.88 Million |
| Abcellera Biologics Inc (ABCL) | $10.25 Million | -21.57% | 1.29x | $1.07 Billion |
| Abeona Therapeutics Inc (ABEO) | $3.60 Million | -91.89% | 0.28x | $292.09 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $266.97 Million | -19.62% | 0.16x | $171.87 Million |
| Abpro Holdings, Inc. (ABP) | $3.07 Million | -479.81% | 1.57x | $448.19K |
| Absci Corp (ABSI) | $67.00 Million | -21.42% | 0.32x | $345.85 Million |
| Arbutus Biopharma Corp (ABUS) | $88.00 Million | -44.09% | 0.34x | $840.56 Million |
| ABVC Biopharma Inc (ABVC) | $80.00K | -31.70% | 0.38x | $26.41 Million |
| Abivax SA American Depositary Shares (ABVX) | $40.58 Million | -434.26% | 4.06x | $9.33 Billion |
| ACADIA Pharmaceuticals Inc (ACAD) | $23.36 Million | -97.44% | 0.37x | $3.74 Billion |
About Unicycive Therapeutics Inc
Unicycive Therapeutics, Inc., a clinical-stage biotechnology company, identifies, develops, and commercializes therapies to address unmet medical needs in the United States. Its drug candidates include UNI 494, a pro-drug of Nicorandil that is being developed as a treatment for acute kidney injury; and Renazorb RZB 012 for the treatment of hyperphosphatemia in patients with chronic kidney disease… Read more